Emerging data on the use of anti‐tumor necrosis factor‐alpha medications in pregnancy
- 11 July 2012
- journal article
- review article
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (8), 607-611
- https://doi.org/10.1002/bdra.23033
Abstract
Anti‐tumor necrosis factor (TNF) α medications are used for the treatment of a number of autoimmune diseases. Evaluation of pregnancy safety for these medications is complicated by the contribution of the underlying maternal disease to adverse pregnancy outcomes, such as preterm delivery and reduced birth weight. Placental transport of these medications is thought to be minimal in the first trimester, thereby providing some reassurance regarding theoretical risks for congenital malformations. Available human exposure data are sparse; however, to date there has been no convincing evidence to support an increased risk for a specific pattern of major congenital malformations with any of the drugs in this group for which some data is currently available. As a result of the improvement of symptoms during pregnancy in some women with autoimmune diseases, it may be possible to discontinue treatment before or shortly after conception. However, in some cases the benefits of treatment and concerns for disease flares in pregnancy have warranted continued treatment during pregnancy. Because of the relatively long half‐life of these medications, and theoretical concerns for immune compromise of the infant following exposure in the latter two trimesters, some clinicians recommend discontinuation of treatment in the third trimester to avoid potentially prolonged infant exposure in the postpartum period. Currently ongoing controlled cohort studies for some of the TNF blocker medications will help to provide more definitive answers for clinicians and patients. Birth Defects Research (Part A) 94:607–611, 2012.Keywords
This publication has 27 references indexed in Scilit:
- Patterns of medication use during pregnancy in rheumatoid arthritisArthritis Care & Research, 2011
- Pregnancy in autoimmune rheumatic diseases: The importance of counselling for old and new challengesAutoimmunity Reviews, 2010
- Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's DiseaseJournal of Crohn's and Colitis, 2010
- Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasisBritish Journal of Dermatology, 2010
- Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feedingInflammatory Bowel Diseases, 2010
- Birth outcomes in women who have taken leflunomide during pregnancyArthritis & Rheumatism, 2010
- Do Tumor Necrosis Factor Inhibitors Cause Malformations in Humans?The Journal of Rheumatology, 2009
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- Exposition to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literatureJoint Bone Spine, 2009
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisThe American Journal of Gastroenterology, 2004